ALLO - Allogene Therapeutics Announces Participation in November Investor Conferences | Benzinga
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that it will participate in two upcoming investor conferences in November.
TD Cowen's 7th Annual Fall Oncology Innovation Summit
Friday, November 3, 2023
8:30AM PT/11:30AM ET
Jefferies London Healthcare Conference
November 15, 2023
4:30AM PT/7:30AM ET/1:30PM GMT
Any available webcasts will be posted to the Company's website at www.allogene.com under the Investors tab in the News and Events section. Following a live webcast, a replay will be available on the Company's website for approximately 30 days.
About Allogene Therapeutics
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) products for cancer. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of "off-the-shelf" ...